T. Rowe Price Investment Management Inc. Has $2.79 Billion Stock Position in Becton, Dickinson and Company $BDX

T. Rowe Price Investment Management Inc. reduced its holdings in shares of Becton, Dickinson and Company (NYSE:BDX) by 11.4% during the fourth quarter, HoldingsChannel.com reports. The fund owned 14,378,219 shares of the medical instruments supplier’s stock after selling 1,854,413 shares during the quarter. Becton, Dickinson and Company makes up approximately 1.8% of T. Rowe Price Investment Management Inc.’s investment portfolio, making the stock its 7th largest position. T. Rowe Price Investment Management Inc. owned approximately 0.05% of Becton, Dickinson and Company worth $2,790,381,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also bought and sold shares of BDX. Imprint Wealth LLC bought a new position in Becton, Dickinson and Company in the 3rd quarter valued at $25,000. Steph & Co. boosted its holdings in shares of Becton, Dickinson and Company by 95.6% in the 4th quarter. Steph & Co. now owns 133 shares of the medical instruments supplier’s stock worth $26,000 after buying an additional 65 shares during the last quarter. Prosperity Bancshares Inc bought a new position in Becton, Dickinson and Company during the fourth quarter valued at about $29,000. Accredited Wealth Management LLC grew its position in Becton, Dickinson and Company by 77.8% during the third quarter. Accredited Wealth Management LLC now owns 160 shares of the medical instruments supplier’s stock valued at $30,000 after buying an additional 70 shares during the period. Finally, WPG Advisers LLC increased its holdings in Becton, Dickinson and Company by 64.2% during the fourth quarter. WPG Advisers LLC now owns 156 shares of the medical instruments supplier’s stock worth $30,000 after buying an additional 61 shares during the last quarter. Hedge funds and other institutional investors own 86.97% of the company’s stock.

Insiders Place Their Bets

In other Becton, Dickinson and Company news, EVP Michael David Garrison sold 1,100 shares of the company’s stock in a transaction dated Wednesday, June 10th. The stock was sold at an average price of $151.48, for a total value of $166,628.00. Following the transaction, the executive vice president directly owned 14,272 shares in the company, valued at $2,161,922.56. This represents a 7.16% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Thomas E. Polen, Jr. sold 2,764 shares of Becton, Dickinson and Company stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $146.35, for a total value of $404,511.40. Following the sale, the chief executive officer owned 110,163 shares of the company’s stock, valued at approximately $16,122,355.05. This trade represents a 2.45% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 4,013 shares of company stock worth $593,434 in the last quarter. 0.40% of the stock is currently owned by company insiders.

Analyst Ratings Changes

Several brokerages have commented on BDX. Royal Bank Of Canada set a $175.00 price objective on shares of Becton, Dickinson and Company in a research report on Tuesday, April 14th. Stifel Nicolaus decreased their price target on shares of Becton, Dickinson and Company from $215.00 to $175.00 in a research note on Thursday, May 7th. Barclays lifted their price target on shares of Becton, Dickinson and Company from $202.00 to $204.00 and gave the stock an “overweight” rating in a report on Monday, May 11th. Weiss Ratings downgraded Becton, Dickinson and Company from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Monday, May 11th. Finally, Bank of America reduced their price objective on Becton, Dickinson and Company from $177.00 to $170.00 in a report on Friday, June 12th. Seven research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Becton, Dickinson and Company has an average rating of “Hold” and a consensus price target of $181.00.

Becton, Dickinson and Company Stock Up 1.7%

BDX stock opened at $143.99 on Friday. The stock has a 50-day simple moving average of $149.15 and a two-hundred day simple moving average of $172.51. Becton, Dickinson and Company has a twelve month low of $127.59 and a twelve month high of $187.35. The firm has a market capitalization of $39.67 billion, a PE ratio of 36.45, a PEG ratio of 10.02 and a beta of 0.22. The company has a quick ratio of 0.55, a current ratio of 0.94 and a debt-to-equity ratio of 0.62.

Becton, Dickinson and Company (NYSE:BDX) last posted its earnings results on Thursday, May 7th. The medical instruments supplier reported $2.90 earnings per share for the quarter, topping analysts’ consensus estimates of $2.77 by $0.13. Becton, Dickinson and Company had a net margin of 5.33% and a return on equity of 15.37%. The business had revenue of $4.71 billion for the quarter, compared to analyst estimates of $4.67 billion. During the same quarter in the prior year, the firm posted $3.35 EPS. Becton, Dickinson and Company’s revenue was up 5.2% on a year-over-year basis. Becton, Dickinson and Company has set its FY 2026 guidance at 12.520-12.720 EPS. On average, equities analysts predict that Becton, Dickinson and Company will post 12.61 EPS for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, June 30th. Stockholders of record on Tuesday, June 9th will be issued a $1.05 dividend. The ex-dividend date of this dividend is Tuesday, June 9th. This represents a $4.20 annualized dividend and a dividend yield of 2.9%. Becton, Dickinson and Company’s dividend payout ratio is presently 106.33%.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.